Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cyberonics (cybx) epilepsy therapy recommonded -- Ignore unavailable to you. Want to Upgrade?

To: Dennis who wrote (235)	4/2/1998 11:02:00 AM
From: Jim Lang	Read Replies (2) \| Respond to of 471

Dennis, The WE is me and my spouse!! She is actually the one that follows the medical related stocks in the house and the one that currently holds CYBX shares, although we both played it (in IRAs) very profitably last year after FDA approval. I just happen to be the one with more time to post messages!! I think that you are right about the monopoly aspect. At present, neither CYBX nor THRX have significant competition on the horizon, so investor confidence is bolstered. But take a look at what happens when competition does come in; WPI (Watson Pharmaceuticals) took a big dive a couple weeks back on word that Mylan Labs (MYL-AMEX) had received approval to market a second generic version of some drug that happened to be the biggest money-maker for WPI (generic also). Fortunately, I'm not aware of anything so close to realization with respect to CYBX, in spite of recent announcements by other companies. Jim Lang